Literature DB >> 22124366

Urological cancer: an axis for renal cell carcinoma treatment.

M Teresa Villanueva.   

Abstract

Entities:  

Year:  2011        PMID： 22124366     DOI： 10.1038/nrclinonc.2011.180

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Authors:  Brian I Rini; Bernard Escudier; Piotr Tomczak; Andrey Kaprin; Cezary Szczylik; Thomas E Hutson; M Dror Michaelson; Vera A Gorbunova; Martin E Gore; Igor G Rusakov; Sylvie Negrier; Yen-Chuan Ou; Daniel Castellano; Ho Yeong Lim; Hirotsugu Uemura; Jamal Tarazi; David Cella; Connie Chen; Brad Rosbrook; Sinil Kim; Robert J Motzer
Journal:  Lancet       Date:  2011-11-04       Impact factor: 79.321
  1 in total
  1 in total

Review 1.  Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.

Authors:  Adriana Petrazzuolo; M Chiara Maiuri; Laurence Zitvogel; Guido Kroemer; Oliver Kepp
Journal:  Oncoimmunology       Date:  2022-05-26       Impact factor: 7.723
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.